The effect of rs5758550 on CYP2D6*2 phenotype and formation of endoxifen in breast cancer patients using tamoxifen

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Senkus E, Kyriakides S, Ohno S et al. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 26(Suppl. 5), v8–v30 (2015).
  MedlineGoogle Scholar
• 2 Burstein HJ, Lacchetti C, Anderson H et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression. J. Clin. Oncol. 34(14), 1689–1701 (2016).
  Medline CASGoogle Scholar
• 3 Kiyotani K, Mushiroda T, Nakamura Y, Zembutsu H. Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. Drug Metab. Pharmacokinet. 27(1), 122–131 (2012).
  Medline CASGoogle Scholar
• 4 Brauch H, Mürdter TE, Eichelbaum M, Schwab M. Pharmacogenomics of tamoxifen therapy. Clin. Chem. 55(10), 1770–1782 (2009).
  Medline CASGoogle Scholar
• 5 Desta Z. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310(3), 1062–1075 (2004).
  Medline CASGoogle Scholar
• 6 Daly AK. Polymorphic variants of cytochrome P450: relevance to cancer and other diseases. Adv. Pharmacol. 74, 85–111 (2015).
  Medline CASGoogle Scholar
• 7 Haufroid V, Hantson P. CYP2D6 genetic polymorphisms and their relevance for poisoning due to amphetamines, opioid analgesics and antidepressants. Clin. Toxicol. 53, 501–510 (2015).
  CASGoogle Scholar
• 8 Zhou S. Polymorphism of human cytochrome P450 2D6 and its clinical significance. Clin. Pharmacokinet. 48(11), 689–723 (2009).
  Medline CASGoogle Scholar
• 9 Hu X, Zhou Q, Lan T et al. Functional characterization of 22 novel CYP2D6 variants for the metabolism of tamoxifen. J. Pharm. Pharmacol. 68(6), 819–825 (2016).
  Medline CASGoogle Scholar
• 10 Goetz M, Rae J, Suman V et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23(36), 9312–9318 (2005). • Describes the association between clinical outcomes in tamoxifen-treated patients and the pharmacogenetics of tamoxifen biotransformation. Along with the article by Goetz et al., describes the relationship between the clinical outcomes and CYP2D6 influence in tamoxifen transformation.
  Medline CASGoogle Scholar
• 11 Schroth W, Antoniadou L, Fritz P et al. Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes. J. Clin. Oncol. 25(33), 5187–5193 (2007).
  Medline CASGoogle Scholar
• 12 Madlensky L, Natarajan L, Tchu S et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin. Pharmacol. Ther. 89(5), 718–725 (2011). • Describes a threshold above which endoxifen is effective against the recurrence of breast cancer.
  Medline CASGoogle Scholar
• 13 Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst. 97(1), 30–39 (2005).
  Medline CASGoogle Scholar
• 14 Dezentjé VO, Guchelaar HJ, den Hartigh J et al. A prospective study on the effect of CYP2D6 genotype and pharmacokinetics on clinical outcome in tamoxifen treated early breast cancer patients (CYPTAM study) [PhD Thesis]. Leiden University, Leiden, The Netherlands (2014). https://openaccess.leidenuniv.nl/.
  Google Scholar
• 15 Wang D, Poi MJ, Sun X, Gaedigk A, Leeder JS, Sadee W. Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity. Hum. Mol. Genet. 23(1), 268–278 (2014).
  Medline CASGoogle Scholar
• 16 Wang D, Papp AC, Sun X. Functional characterization of CYP2D6 enhancer polymorphisms. Hum. Mol. Genet. 24(6), 1556–1562 (2015). • In this study, Wang et al., the relationship between the rs5758550 SNP and the CYP2D6*2 allele is presented.
  Medline CASGoogle Scholar
• 17 CYP2D6*2. Pharmgkborg. www.pharmgkb.org/haplotype/PA165816577#tabview=tab3&subtab.
  Google Scholar
• 18 Dezentje VO, Hartigh de J, Guchelaar H et al. Association between endoxifen serum concentration and predicted CYP2D6 phenotype in a prospective cohort of patients with early-stage breast cancer. J. Clin. Oncol. 29(15), Suppl. Abstr. 56 (2011).
  Google Scholar
• 19 Teunissen SF, Rosing H, Koornstra RHT et al. Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 877(24), 2519–2529 (2009).
  CASGoogle Scholar
• 20 Brown JT, Abdel-Rahman SM, van Haandel L, Gaedigk A, Lin YS, Leeder JS. Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. Clin. Pharmacol. Ther. 99(6), 642–650 (2016).
  Medline CASGoogle Scholar
• 21 Common Fund (CF) Genotype-Tissue Expression Project (GTEx). www.gtexportal.org/home/eqtls/bySnp?snpId=rs5758550&tissueName=All.
  Google Scholar